HK1010153A1 - Recombinant human alpha-fetoprotein and uses thereof. - Google Patents

Recombinant human alpha-fetoprotein and uses thereof.

Info

Publication number
HK1010153A1
HK1010153A1 HK98111257A HK98111257A HK1010153A1 HK 1010153 A1 HK1010153 A1 HK 1010153A1 HK 98111257 A HK98111257 A HK 98111257A HK 98111257 A HK98111257 A HK 98111257A HK 1010153 A1 HK1010153 A1 HK 1010153A1
Authority
HK
Hong Kong
Prior art keywords
fetoprotein
recombinant human
human alpha
alpha
recombinant
Prior art date
Application number
HK98111257A
Other languages
English (en)
Inventor
Robert A Murgita
Original Assignee
Robert A Murgita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Robert A Murgita filed Critical Robert A Murgita
Publication of HK1010153A1 publication Critical patent/HK1010153A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
HK98111257A 1995-01-24 1998-10-15 Recombinant human alpha-fetoprotein and uses thereof. HK1010153A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37731795A 1995-01-24 1995-01-24
US37731695A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
PCT/US1996/000996 WO1996022787A1 (en) 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof

Publications (1)

Publication Number Publication Date
HK1010153A1 true HK1010153A1 (en) 1999-06-17

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98111257A HK1010153A1 (en) 1995-01-24 1998-10-15 Recombinant human alpha-fetoprotein and uses thereof.

Country Status (7)

Country Link
EP (1) EP0805687A4 (zh)
JP (2) JPH10513347A (zh)
CN (1) CN1150030C (zh)
AU (1) AU700975B2 (zh)
CA (1) CA2211324C (zh)
HK (1) HK1010153A1 (zh)
WO (1) WO1996022787A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
EP0979239B1 (en) * 1997-02-13 2006-10-18 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
DE60037397T2 (de) * 1999-01-06 2008-06-05 Merrimack Pharmaceuticals, Inc., Cambridge Expression von ausgeschiedenem, menschlichem alpha-fetoprotein in transgenen tieren
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
WO2001003501A2 (en) * 1999-07-12 2001-01-18 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
KR100482920B1 (ko) * 2000-02-10 2005-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간세포암을 치료하기 위한 조성물
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20060111289A1 (en) * 2004-09-09 2006-05-25 Serometrix, Llc, Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
AU2007338771A1 (en) * 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术(广东)有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインi遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインiの製造法及び製造された該ドメインi
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
AU2649592A (en) * 1991-09-25 1993-04-27 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
JPH10506204A (ja) * 1994-09-26 1998-06-16 シーメンス アクチエンゲゼルシヤフト Oeicモジュールおよび光ファイバを光学的に相互結合するための結合装置

Also Published As

Publication number Publication date
EP0805687A4 (en) 2000-05-31
AU700975B2 (en) 1999-01-14
WO1996022787A1 (en) 1996-08-01
CN1150030C (zh) 2004-05-19
AU4903596A (en) 1996-08-14
EP0805687A1 (en) 1997-11-12
CN1179106A (zh) 1998-04-15
JP2008073041A (ja) 2008-04-03
JPH10513347A (ja) 1998-12-22
CA2211324C (en) 2012-07-10
CA2211324A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
IL122428A0 (en) Minizymes and minribozymes and uses thereof
HK1096974A1 (en) Antibody against human parathormone related peptides
HUP9902698A3 (en) Human bikunin
EP0790826A4 (en) DYHYDROPYRIMIDINE AND THEIR USE
HK1010153A1 (en) Recombinant human alpha-fetoprotein and uses thereof.
EP0768038A3 (en) Shortening and its use
GB9500601D0 (en) Modified peptides
ZA964825B (en) Collagen peptide fraction and its uses.
ZA9410217B (en) Recombinant human thymopoietin proteins and uses therefor.
EP0836617A4 (en) PAREVINES AND TACHYTEGRINES
ZA96240B (en) Novel peptides their preparation and use
ZA964862B (en) Optimized minizymes and miniribozymes and uses thereof
EP0828512A4 (en) PROTEIN (BIN1) MURINE AND HUMAN DEPENDENT ON BOXES, INTERACTING WITH MYC, AND USES THEREOF
EP1012262A4 (en) HFLP PROTEIN HFLP
PL324822A1 (en) Human protein mp52 arg
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
GB9423372D0 (en) Proteins and their uses
ZA96239B (en) Novel peptides their preparation and use
EP0744125A3 (en) Iodine complex and its application
EP0841393A4 (en) HUMAN GALECTIN-4-LIKE PROTEIN AND ENCODING DNA
GB9519865D0 (en) Protein
PL327175A1 (en) Novel peptides, their production and application
GB9622436D0 (en) Protein
EP0857732A4 (en) HUMAN PROTEIN ANALOGUE TO PEC-60 AND THE DNA THAT ENCODES IT
AU3894497A (en) Novel human glycoprotein

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: RICHARD BOISMENU

PE Patent expired

Effective date: 20160123